

Prescribers Guide: TPP SystmOne

FDB OptimiseRx is fully integrated into the prescribing workflow within TPP SystmOne. OptimiseRx uses the medication prescribed, and in some cases patient specific criteria, medication and condition history to determine whether an OptimiseRx message is relevant to present to the prescriber at the point of care.

OptimiseRx messages may appear when initiating a medication for the first time, reauthorisation of individual medications and re-prescribing a past medication.

There are three types of message that could be presented when a medication is selected:

- Formulary
- Best Practice Guidance or Cost Saving (where there are multiple Alternative Products)
- Information e.g. monitoring guidance

A further message type may be displayed at the end of the prescribing workflow after completion of dosage and quantity information and these are referred to as Simple Cost Messages.

Best Practice Guidance messages and Cost Saving messages with Multiple Alternative Products

Headline message for quick reference

Click this box to accept message and reveal the Alternative Products (see P2)

Click overrule or overrule with reason to reject the message and proceed with the original selection (see also P3)

OptimiseRx Warnings for Erythromycin stearate 250mg tablets

▼ Expand All ▶ Collapse All

Reset All Warnings Overrule All with Reason Overrule All

Clarithromycin tablets are recommended for susceptible infections if a macrolide antibiotic is required in non-pregnant patients.

✓ Show 2 Suggestions Overrule with Reason Overrule

• NICE/UKHSA (Jun 2023) recommends clarithromycin as the preferred macrolide. Clarithromycin has longer serum half-life and better tissue penetration than erythromycin, allowing reduced dosing frequency offering improved compliance.

• Clarithromycin does not share all the indications of erythromycin. Refer to local antibiotic guidance for details of conditions for which erythromycin, but not clarithromycin, should be used.

References [NICE](#) [elearning.rcgp.org.uk](#) [electronic Medicines Compendium](#) [electronic Medicines Compendium](#)

[Why is this warning showing?](#)

Disclaimer: The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance [View Full Disclaimer](#)


Proceed with Alternative Proceed with Original Do Not Proceed

Click here to see the attributes in the patient record which led to the message being presented.


Click on the hyperlinks for direct access the local or national guidance

The options to proceed with the Alternative Product or Original Medications are enabled once the messages have been acknowledged by the Overrule or Show Suggestions buttons above

Accepting a message takes two steps; click to view the locally approved Alternative Products and then select which of these to prescribe.



Opens this dialog box below



List of Alternatives Products

1. Click on the chosen Alternative Product
2. Click OK


NB SystmOne may 'hide' medicines from the list of Alternative Products where those medicines have been identified as having patient specific warnings e.g. drug-drug interactions and patient sensitivities.

Reveal these by clicking on the tick-box titled 'Hide drugs with warnings'.


To Reject a Message

Providing feedback on the rejection of a message is an optional step either by selecting a pre-defined comment or adding free text. If entering a rejection reason, it is recommended that the freetext option is used as this allows you to provide more useful feedback. Any reasons entered will be made available in a report which for colleagues in the ICB/LHB Medicines Optimisation Team to assist in managing the configuration of OptimiseRx. FDB will also review these reasons and use to support message review and updates

If multiple messages have appeared in the dialog box they can be rejected as a group.



A message can be rejected with or without giving a reason for the rejection.



The reason for a rejected message is optional and users can select from the pre-defined list or enter free text by selecting 'Other Reason' from the dropdown. It is recommended that users use this option to provide feedback



Simple Cost Saving Messages

Simple Cost Saving messages will appear once the quantity and dosage information has been entered as this is used to calculate that a saving is available.

OptimiseRx Cost Savings for Erythromycin 250mg gastro-resistant capsules

Original	Suggested
Erythromycin 250mg gastro-resistant capsules	Erythromycin 250mg gastro-resistant tablets
28 capsules	28 tablets
Generic	Generic
£5.61	£1.28

Total saving: £4.33

Disclaimer: The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance [View Full Disclaimer](#)

Use Original Use Alternative Cancel

Continues prescribing of the original medication

Replaces the original drug with the alternative in the prescribing screen.

Returns to the record medication screen.

On accepting a simple Cost Saving message, should the default dose of the Alternative Product medication differ to that initial medication entered, an option to choose the most appropriate dosage statement will be offered.

Question

The OptimiseRx alternative medication you have selected has a different default dose.

Select the dose you would like to use for Erythromycin 250mg gastro-resistant tablets.

Default dose: take one 4 times/day
Original dose: take as directed

All instructions and quantities should be checked prior to prescribing.

Use Default Dose Use Original Dose

Prescribes the Alternative Product using the dose that the user entered for the initial medication.

Changes dose to the default dose for the medication that OptimiseRx message has presented as an Alternative Product.

To Acknowledge an Information Message

OptimiseRx Warnings for Metformin 500mg tablets

▼ Expand All ► Collapse All

Monitor the patient's serum creatinine; no result recorded within 1 year

- A Royal College of General Practitioners (RCGP) indicator (2014) to assess the safety of prescribing states that prescribing metformin without an annual serum creatinine check is potentially hazardous and may put those patients at risk of harm. Renal function should be checked before therapy begins and regularly (e.g. annually) thereafter.
- Metformin is mainly excreted via the kidneys; any loss in renal function would lead to a rise in metformin concentration thus increasing the risk of potential side effects, such as lactic acidosis.

References bjgp.org

[Why is this warning showing?](#)

Disclaimer: The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance [View Full Disclaimer](#)

Proceed

The Best Practice guidance in an Information message can be acknowledged by clicking Proceed.



RAG / Formulary Message

Your local organisation can configure whether a message appears with a red or amber banner; red usually indicates that a product shouldn't be prescribed and amber is often reserved for medications that are subject to shared care arrangements.

OptimiseRx Warnings for Adalimumab 20mg/0.2ml solution for injection pre-filled syringes

▼ Expand All ► Collapse All

The selected product is classified as RED - do not prescribe

- Only suitable for use within hospital or specialist care setting.

References [electronic Medicines Compendium](#) [dmo-pi-admin@1.azurewebsites.net](#)

[Why is this warning showing?](#)

Disclaimer: The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance [View Full Disclaimer](#)

Proceed

OptimiseRx Warnings for Adoport 2mg capsules (Sandoz Ltd)

▼ Expand All ► Collapse All

The selected product is classified as AMBER SHARED CARE

- Drugs requiring initiation by a specialist, but with the potential to transfer to primary care, within written and agreed shared care frameworks, and according to the agreed process for transfer of care. Transfer to primary care is expected to be the normal practice.

References www.hey.nhs.uk

[Why is this warning showing?](#)

Disclaimer: The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance [View Full Disclaimer](#)

Proceed

To 'accept' the advice of a red/do not prescribe message, click on Proceed to acknowledge and then delete drug from prescribed drug field